Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:47 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 93 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: peginterferon alfa-2b Clear all

Conditions: Hepatitis C, Chronic
Interventions: Viramidine, Peginterferon alfa-2b; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 11
States / cities: Los Angeles, California • San Mateo, California • Bradenton, Florida + 8 more

Conditions: Anemia, Liver Disease, Hypoxemia
Interventions: Pegylated Interferon Alpha2b, Standard care; Drug · Other
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Malignant Melanoma
Interventions: Peginterferon alfa-2b, Temozolomide, Recombinant interferon alfa-2b; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 21 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2031
U.S. locations: 3
States / cities: San Diego, California • Memphis, Tennessee • Houston, Texas

Conditions: Melanoma
Interventions: Temozolomide (TMZ), Pegylated Interferon Alpha-2b (PGI); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Melanoma
Interventions: Decitabine, Pegylated Interferon Alpha-2b; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Metastatic Gastrointestinal Carcinoid Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Regional Gastrointestinal Carcinoid Tumor
Interventions: PEG-interferon alfa-2b, bevacizumab, laboratory biomarker analysis; Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
Interventions: PEG-interferon alfa-2b, PEG-interferon alfa-2b; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Renal Cell
Interventions: Pegylated Alfa Interferon, sunitinib, erlotinib; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Hepatitis C
Interventions: Interferon-alpha; Drug
Lead sponsor: University of Arizona; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Tucson, Arizona • Atlanta, Georgia

Conditions: Hepatitis C, Chronic
Interventions: Peginterferon alfa-2a [Pegasys], Peginterferon alfa-2b [PegIntron®]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 1,656 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 105
States / cities: Birmingham, Alabama • Dothan, Alabama • Fresno, California + 86 more

Conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Interventions: Autologous Monocytes + ACTIMMUNE + SYLATRON; Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Eltrombopag, Antiviral therapy; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 6
States / cities: San Diego, California • New Haven, Connecticut • Honolulu, Hawaii + 3 more

Conditions: Adult T-cell Leukemia-Lymphoma, ATLL
Interventions: Belinostat, Zidovudine, Interferon-Alfa-2b, Pegylated Interferon-Alfa-2b, Lymphodepleting Therapy; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Not Otherwise Specified, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Questionnaire Administration, Ropeginterferon Alfa-2B; Procedure · Other · Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Melanoma
Interventions: HyperAcute vaccine, Pegylated Interferon-Alpha 2b; Biological · Drug
Lead sponsor: Ochsner Health System; Other
Eligibility: 19 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Chronic Hepatitis C
Interventions: Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin; Drug
Lead sponsor: InterMune; Industry
Eligibility: 18 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Brisbane, California

Conditions: Diffuse Intrinsic Pontine Glioma
Interventions: adjuvant therapy, pegylated interferon alfa; Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Up to 21 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hepatitis C
Interventions: Telaprevir, Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 3 Years to 17 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 13
States / cities: Phoenix, Arizona • San Francisco, California • Denver, Colorado + 10 more

Conditions: Hepatitis C Infection
Interventions: Boceprevir; Drug
Lead sponsor: Arrowhead Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Riverside, California

Conditions: Leukemia, Myeloid, Philadelphia-Positive
Interventions: PEG-Intron; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelofibrosis
Interventions: Peginterferon alfa-2a; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • New York, New York

Conditions: Hepatitis C, Chronic
Interventions: eltrombopag, placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 759 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 59
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 49 more

Conditions: Plexiform Neurofibroma
Interventions: PEG-Intron; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Months to 21 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: HIV Infections
Interventions: Peginterferon alfa-2b; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 16 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2004
U.S. locations: 15
States / cities: Long Beach, California • Los Angeles, California • San Francisco, California + 11 more

Search by objective public record fields.

Viral Kinetic Study With Viramidine in Therapy-Naive Patients With Chronic Hepatitis C

Phase 2 Study of PEG-Intron in Hereditary Hemorrhagic Telangiectasia

Phase II Study Incorporating Pegylated Interferon In the Treatment For Children With High-Risk Melanoma

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Parallel Phase I/II Trial of Decitabine and Peg-Interferon in Melanoma: Phase I Portion

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

PEG-Interferon Alfa-2b in Treating Patients With Platinum-Resistant Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer

Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic RCC

Inflammation, Stress & Social Behavior: Using Ecological Assessments & Model Systems to Enhance Relevance to Health Outcomes

PROPHESYS 3: Observational Study on Predictors of Response in Patients With Treatment-naïve Chronic Hepatitis C Initiated on Treatment With Pegasys (Peginterferon Alfa-2a) or Peginterferon-alfa-2b

Intraperitoneal Infusion of Autologous Monocytes With Sylatron (Peginterferon Alfa-2b) and Actimmune (Interferon Gamma-1b) in Women With Recurrent or Refractory Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer

Clinical Trial for Non-responders Who Previously Participated in Eltrombopag Studies TPL 103922 or TPL 108390

Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma

Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia

A Phase II Study of an Anti-Tumor Immunotherapy Regimen Comprised of Pegylated Interferon-Alpha 2b and HyperAcute Melanoma Vaccine for Subjects With Advanced Melanoma

CIFN and IFN γ-1b With or Without Ribavirin for Treatment of Chronic Hepatitis C (Nonresponders)

A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Treating Hispanic Patients Diagnosed With Hepatitis C Using Boceprevir

PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or Intron

Pegylated Interferon Alpha-2b in Early Primary Myelofibrosis

Eltrombopag To Initiate And Maintain Interferon Antiviral Treatment To Benefit Subjects With Hepatitis C Liver Disease

Study of PEG-Intron for Plexiform Neurofibromas

Safety, Tolerability, and Anti-HIV Activity of PEG-Intron in HIV-Positive Children